Copyright
©The Author(s) 2004.
World J Gastroenterol. Jul 1, 2004; 10(13): 1893-1897
Published online Jul 1, 2004. doi: 10.3748/wjg.v10.i13.1893
Published online Jul 1, 2004. doi: 10.3748/wjg.v10.i13.1893
SENV positive (n = 21) | SENV negative (n = 74) | P value | |
Median age (yr) | 42 ± 12 | 42 ± 12 | 0.991 |
Male, m (%) | 13 (62%) | 46 (62%) | 1.002 |
Median baseline ALT (IU/L ) | 81 ± 109 | 69 ± 60 | 0.561 |
Pretreated, n (%) | 3 (14%) | 10 (14%) | 1.002 |
Hepatitis C genotype, n (%) | |||
1, 4 | 16 (76%) | 51 (69%) | 0.602 |
2, 3 | 5 (24%) | 21 (28%) | 0.792 |
Undetermined | 0 (0%) | 2 (3%) | |
PEG-IFN | 11 (52%) | 35 (47%) | 0.812 |
Sustained HCV response to therapy | 11 (52%) | 37 (50%) | 1.002 |
- Citation: Sagir A, Adams O, Kirschberg O, Erhardt A, Heintges T, Häussinger D. SEN virus does not affect treatment response in hepatitis C virus coinfected patients but SEN virus response depends on SEN virus DNA concentration. World J Gastroenterol 2004; 10(13): 1893-1897
- URL: https://www.wjgnet.com/1007-9327/full/v10/i13/1893.htm
- DOI: https://dx.doi.org/10.3748/wjg.v10.i13.1893